255 related articles for article (PubMed ID: 29940880)
1. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
2. Associations between essential medicines and health outcomes for cardiovascular disease.
Steiner L; Fraser S; Maraj D; Persaud N
BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933
[TBL] [Abstract][Full Text] [Related]
3. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
4. Essential medicines for breast cancer in low and middle income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
BMC Cancer; 2015 Aug; 15():591. PubMed ID: 26283654
[TBL] [Abstract][Full Text] [Related]
5. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517
[TBL] [Abstract][Full Text] [Related]
6. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
7. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
8. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
[TBL] [Abstract][Full Text] [Related]
10. Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries.
Samukange WT; Gardarsdottir H; Leufkens HGM; Mantel-Teeuwisse AK
Transfus Med Rev; 2020 Apr; 34(2):94-100. PubMed ID: 31761652
[TBL] [Abstract][Full Text] [Related]
11. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.
Wirtz VJ; Kaplan WA; Kwan GF; Laing RO
Circulation; 2016 May; 133(21):2076-85. PubMed ID: 27217433
[TBL] [Abstract][Full Text] [Related]
12. Essential medicines for COPD and asthma in low and middle-income countries.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
Thorax; 2014 Dec; 69(12):1149-51. PubMed ID: 24590803
[TBL] [Abstract][Full Text] [Related]
13. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
14. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
15. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
16. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries.
Kishore SP; Vedanthan R; Fuster V
J Am Coll Cardiol; 2011 May; 57(20):1980-7. PubMed ID: 21565635
[TBL] [Abstract][Full Text] [Related]
17. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.
McGettigan P; Henry D
PLoS Med; 2013; 10(2):e1001388. PubMed ID: 23424288
[TBL] [Abstract][Full Text] [Related]
18. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon.
Jingi AM; Noubiap JJ; Ewane Onana A; Nansseu JR; Wang B; Kingue S; Kengne AP
PLoS One; 2014; 9(11):e111812. PubMed ID: 25369455
[TBL] [Abstract][Full Text] [Related]
19. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
[TBL] [Abstract][Full Text] [Related]
20. Essential diabetes medicines and health outcomes in 127 countries.
Budhram D; Benipal S; Bilimoria K; Maraj D; Wang R; Persaud N
Diabetes Obes Metab; 2021 May; 23(5):1121-1128. PubMed ID: 33417268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
